Clinical Scorecard: The association of glucose regulation and prostate volume in older Chinese men with benign prostatic hyperplasia
At a Glance
Category
Detail
Condition
Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS)
Key Mechanisms
Unregulated proliferation of stromal and epithelial prostate cells influenced by aging and metabolic diseases including diabetes and prediabetes
Target Population
Middle-aged and elderly Chinese men with symptomatic BPH undergoing prostate surgery
Care Setting
Urology department with surgical intervention (transurethral resection of the prostate)
Key Highlights
Diabetes is significantly associated with increased prostate volume in BPH patients.
Prediabetes, a precursor to diabetes, has an unclear but potentially important effect on prostate size.
Prostate volume increases with age, with a faster growth rate before age 70 compared to after.
Guideline-Based Recommendations
Diagnosis
Assess fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) to classify glycemic status per ADA criteria.
Use transrectal ultrasound to measure total prostate volume (TPV) and transitional zone volume (TZV).
Evaluate patient history and exclude confounding conditions such as prostate cancer, neurogenic bladder, and recent hormone or 5ARI use.
Management
Consider metabolic status including diabetes and prediabetes in managing BPH patients.
Indications for TURP include recurrent urinary retention, infections, hematuria, bladder stones/diverticula, upper urinary tract dilation, or patient preference.
Monitoring & Follow-up
Monitor prostate volume growth rates annually, especially before age 70.
Regularly assess glycemic control and metabolic parameters to understand their impact on prostate growth.
Risks
Increased prostate volume is associated with higher prevalence of LUTS and need for surgical intervention.
Metabolic diseases like diabetes may exacerbate prostate enlargement and symptom severity.
Patient & Prescribing Data
Symptomatic BPH patients undergoing TURP, stratified by normoglycemic, prediabetic, and diabetic status
Exclusion of patients on hormones, antiandrogens, steroids, antifungals, or 5-α reductase inhibitors within 6 months to avoid confounding prostate volume assessment
Clinical Best Practices
Classify patients accurately by glycemic status using ADA criteria to identify risk groups.
Use standardized ultrasound measurement techniques for prostate volume assessment.
Consider age and metabolic status interactions when evaluating prostate growth and treatment planning.
Exclude confounding comorbidities and medications that affect prostate size in clinical evaluation.
Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for a steep rise in the number of cases,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, and senior author of a landmark international study published in European Urology, which demonstrates that if current trends continue, kidney cancer cases could double by 2050
